The name Twist Bioscience Corporation (TWST) should be kept on your radar

In the latest session, Twist Bioscience Corporation (NASDAQ: TWST) closed at $25.61 up 3.22% from its previous closing price of $24.81. In other words, the price has increased by $+0.80 from its previous closing price. On the day, 1289929 shares were traded. TWST stock price reached its highest trading level at $26.19 during the session, while it also had its lowest trading level at $24.36.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



For a deeper understanding of Twist Bioscience Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.30 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 25 when Banyai William sold 379 shares for $29.55 per share. The transaction valued at 11,199 led to the insider holds 255,581 shares of the business.

Banyai William sold 318 shares of TWST for $11,493 on Oct 03. The insider now owns 256,161 shares after completing the transaction at $36.14 per share. On Sep 16, another insider, Green Paula, who serves as the SVP of Human Resources of the company, sold 8,514 shares for $37.43 each. As a result, the insider received 318,681 and left with 14,199 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 8.02 while its Price-to-Book (P/B) ratio in mrq is 1.76.

Stock Price History:

Over the past 52 weeks, TWST has reached a high of $114.82, while it has fallen to a 52-week low of $23.90. The 50-Day Moving Average of the stock is 33.61, while the 200-Day Moving Average is calculated to be 40.29.

Shares Statistics:

For the past three months, TWST has traded an average of 1.15M shares per day and 2.52M over the past ten days. A total of 56.29M shares are outstanding, with a floating share count of 55.80M. Shares short for TWST as of Oct 13, 2022 were 5.67M with a Short Ratio of 6.09M, compared to 6.24M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 10.06% and a Short% of Float of 10.16%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$1.06 and a low estimate of -$1.4, while EPS last year was -$0.84. The consensus estimate for the next quarter is -$1.16, with high estimates of -$0.99 and low estimates of -$1.26.

Analysts are recommending an EPS of between -$4.19 and -$5.27 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.8, with 9 analysts recommending between -$4.48 and -$5.55.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $57.02M this quarter.It ranges from a high estimate of $58M to a low estimate of $56.4M. As of the current estimate, Twist Bioscience Corporation’s year-ago sales were $37.95M, an estimated increase of 50.20% from the year-ago figure.

A total of 9 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $204M, while the lowest revenue estimate was $198M, resulting in an average revenue estimate of $202.61M. In the same quarter a year ago, actual revenue was $132.33M, up 53.10% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $256.22M in the next fiscal year. The high estimate is $282M and the low estimate is $154.83M. The average revenue growth estimate for next year is up 26.50% from the average revenue estimate for this year.